LifeVantage (LFVN) Q3 2026 earnings review
GLP-1 Hangover Crushes Top Line, But Capital Returns Persist
LifeVantage is caught in a severe operational downdraft. Revenue collapsed 25.2% YoY to $43.7M as the company's much-hyped MindBody GLP-1 system succumbed to cheaper pharmaceutical competition. More concerning: the recent LoveBiome acquisition, which was heavily promoted as the new growth engine, is completely failing to plug the gap. Active accounts are hemorrhaging across the board. Yet, in a stark contrast to its operational struggles, management maintains a pristine, zero-debt balance sheet and shockingly raised the dividend by 11.1%. The message is clear: top-line growth is broken, but aggressive cost controls are protecting cash flow enough to reward shareholders.
🐂 Bull Case
Despite a collapsing top line, LFVN hiked its quarterly dividend by 11.1% to $0.05 and continues repurchasing shares ($1.6M YTD), supported by a zero-debt balance sheet and $12.5M in cash.
Management successfully stripped out absolute costs. SG&A expenses dropped $3.2M YoY, mitigating the impact of the massive revenue decline on bottom-line profitability.
🐻 Bear Case
The company's previous star product was decimated by pharmaceutical alternatives, forcing continuous inventory obsolescence write-downs and dragging Americas revenue down 28.9%.
Active Consultants dropped 13.5% and Active Customers plunged 27.3% YoY. The direct-selling ecosystem is losing its critical mass, making a turnaround highly difficult.
⚖️ Verdict: 🔴
Bearish. While the balance sheet is a fortress and the dividend hike is a nice headline, the core direct-selling business is rapidly shrinking. A 25% revenue decline is too steep to ignore, and the touted acquisition strategy has not stopped the bleeding.
Key Themes
The Growth Engine is Broken
The narrative from Q1 and Q2 was that the LoveBiome acquisition would replace the dying MindBody GLP-1 segment. The data proves this is failing. Total revenue actually decelerated sequentially from $48.9M in Q2 to $43.7M in Q3. The LoveBiome contribution is simply too small to offset the structural decay in the legacy business.
Hemorrhaging Active Accounts
A direct-selling company lives and dies by its network. In Q3, Active Customers collapsed by 27.3% (down to 64,000) and Active Consultants fell by 13.5% (down to 45,000). The Americas segment took the hardest hit, losing 28,000 total accounts YoY. This indicates that field leaders are defecting and the new product stack is failing to attract a replacement cohort.
Aggressive Cost Containment Protects Margins
If there is a silver lining, it is management's ability to cut costs. Despite a $14.7M YoY drop in revenue, Gross Margin remained exceptionally resilient at 79.4% (excluding $183K in inventory obsolescence). Furthermore, absolute SG&A was slashed from $17.1M to $13.9M, preventing an operating loss. Management is ruthlessly managing the decline.
Lingering Inventory Obsolescence
The hangover from the MindBody GLP-1 overproduction continues. The company booked another allowance for inventory obsolescence this quarter. While smaller than the $2.4M hit in Q2, it remains a persistent drag on GAAP gross profitability and highlights poor demand forecasting.
Other KPIs
Decelerating sharply. Down 50% from $6.4 million in the prior year. The sheer loss of revenue volume deleveraged the business, compressing the Adjusted EBITDA margin from 11.0% down to 7.3%.
Reversing. Down roughly half from the $10.8 million generated in the same nine-month period last year. Despite the drop, it remains positive, enabling the company to fund its dividend and buybacks without taking on debt.
Guidance
Decelerating. Management implicitly lowered the bar, stating they expect to land at the 'lower end' of their previously issued $185M-$200M range. With $140.2M booked YTD, this implies a Q4 revenue target of roughly $44.8M—meaning the top line will remain stagnant sequentially and down nearly 18% YoY in Q4.
Decelerating. Pointing to the lower bound of the prior $0.60-$0.80 range. With $0.45 earned YTD, this implies a Q4 EPS of roughly $0.15, signaling that severe margin compression will persist through the end of the fiscal year.
Key Questions
LoveBiome Performance
You acquired LoveBiome to be the new growth driver, yet total revenue fell sequentially from Q2 to Q3. Is LoveBiome shrinking as well, or is the legacy business eroding so fast it's masking LoveBiome's growth?
Consultant Attrition
With Active Consultants down 13.5% YoY, what specific shifts in the Evolve Compensation Plan are being implemented to stop field leaders from defecting to competitors?
MindBody Inventory Risk
You recorded another inventory obsolescence charge this quarter for the MindBody GLP-1 system. Exactly how much legacy inventory is left on the balance sheet, and when will these write-downs end?